Nanobiotix's NBTXR3 Shows Early Promise in Stage 3 Lung Cancer Trial
Event summary
- Nanobiotix presented first data from the CONVERGE Phase 2 trial evaluating NBTXR3 (JNJ-1900) in stage 3 inoperable lung cancer at the 2026 European Lung Cancer Conference.
- Initial efficacy responses in 7 patients showed an objective response rate (ORR) of 71.4% and disease control rate (DCR) of 100%, exceeding estimated benchmarks of 45%-50%.
- The trial demonstrated an acceptable safety profile with no serious treatment-emergent adverse events.
- NBTXR3 is a first-in-class nanotherapeutic activated by radiotherapy, designed to induce tumor cell death and trigger an adaptive immune response.
The big picture
Nanobiotix's NBTXR3 represents a novel approach to cancer treatment by leveraging nanotechnology to enhance radiotherapy. The early Phase 2 data positions the therapy as a potential game-changer in the treatment of stage 3 inoperable lung cancer, a market with significant unmet needs. The collaboration with Johnson & Johnson provides Nanobiotix with the scale and resources to accelerate development across multiple indications.
What we're watching
- Clinical Validation
- Whether the early efficacy signals in lung cancer can be replicated in larger patient populations and other solid tumors.
- Regulatory Pathway
- The pace at which Nanobiotix and Johnson & Johnson advance NBTXR3 through Phase 3 trials and potential regulatory approvals.
- Commercial Strategy
- How Nanobiotix balances its collaboration strategy with Johnson & Johnson while pursuing other development pathways.
Related topics